Kevin Moulder

Kevin Moulder is a distinguished inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibody polypeptides. With a total of four patents to his name, Moulder is recognized for his innovative approaches to addressing autoimmune disorders.

Latest Patents

Moulder's latest patents focus on methods of antagonizing the binding of CD40 to CD40L using CD40L-specific monovalent polypeptides. These inventions relate to antibody polypeptides that monovalently bind CD40L, which can inhibit CD40L activity while minimizing potential undesirable effects associated with divalent or multivalent binding. One aspect of his invention includes a monovalent anti-CD40L antibody polypeptide that consists of a single immunoglobulin variable domain, specifically designed to bind and antagonize the activity of CD40L. This innovation aims to treat diseases or disorders involving CD40/CD40L interactions by administering a monovalent anti-CD40L antibody polypeptide to individuals.

Career Highlights

Kevin Moulder is currently employed at Domantis Limited, where he continues to advance his research in antibody technology. His work has been pivotal in developing therapeutic strategies for autoimmune diseases, showcasing his commitment to improving patient outcomes through innovative solutions.

Collaborations

Moulder collaborates with notable colleagues, including Steven Grant and Haiqun Liu. Their combined expertise contributes to the advancement of research and development in the field of biotechnology.

Conclusion

Kevin Moulder is a prominent inventor whose work in antibody polypeptide technology has the potential to revolutionize treatments for autoimmune disorders. His innovative patents and collaborations reflect his dedication to scientific advancement and improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.